PHOENIX--(BUSINESS WIRE)--March 31, 2005--GW Medical Technologies, LLC, the worldwide technology provider of the blood test for Alzheimer's disease known as the LymPro(TM) Test, announced today the launch of a pilot study to verify its prior results and make final preparations for FDA-applicable clinical studies.
The study is being conducted as a retrospective blind test with samples from healthy participants, those with Alzheimer's disease as well as patients with other dementias. Test results are expected to demonstrate the LymPro Test's strong correlations with clinical diagnosis.
